Introduction
============

MicroRNAs (miRNAs) are a class of endogenous small noncoding RNAs conserved through the evolution. They mediate posttranscriptional regulation of protein-coding genes by binding to the 3\' untranslated region (3\'UTR) of target mRNAs, leading to translational inhibition, mRNA destabilization or degradation, depending on the degree of sequence complementarity \[[@B1]\]. During the biogenesis of miRNAs, the primary miRNAs (pri-miRNAs) are transcribed from the intra- and inter-genetic regions of the genome by RNA polymerase II, followed by processing by the RNase III enzyme Drosha into pre-miRNAs. After nuclear export, they are cleaved by the RNase III enzyme Dicer into mature miRNAs consisting of approximately 22 nucleotides. Finally, a single-stranded miRNA is loaded onto the RNA-induced silencing complex (RISC), where the seed sequence located at positions 2 to 8 from the 5\' end of the miRNA plays a pivotal role in recognition of the target mRNA \[[@B2]\]. At present, more than one thousand of human miRNAs are registered in miRBase Release 16 <http://www.mirbase.org>. The 3\'UTR of a single mRNA is often targeted by several different miRNAs, while a single miRNA concurrently reduces the production of hundreds of target proteins \[[@B3]\]. Consequently, the whole miRNA system (microRNAome) regulate greater than 60% of all protein-coding genes in a human cell \[[@B4]\]. By targeting multiple transcripts and affecting expression of numerous proteins, miRNAs play a key role in fine-tuning of diverse cellular functions, such as development, differentiation, proliferation, apoptosis and metabolism. Therefore, aberrant regulation of miRNA expression is deeply involved in pathological events that mediate cancers \[[@B5]\] and neurodegenerative disorders \[[@B6]\].

Recent advances in systems biology have made major breakthroughs by illustrating the cell-wide map of complex molecular interactions with the aid of the literature-based knowledgebase of molecular pathways \[[@B7]\]. The logically arranged molecular networks construct the whole system characterized by robustness, which maintains the proper function of the system in the face of genetic and environmental perturbations \[[@B8]\]. In the scale-free molecular network, targeted disruption of limited numbers of critical components designated hubs, on which the biologically important molecular interactions concentrate, efficiently disturbs the whole cellular function by destabilizing the network \[[@B9]\]. Therefore, the identification of the hub in the molecular network constructed by target genes of a particular miRNA helps us to understand biological and pathological roles of individual miRNAs. Recently, Hsu et al. studied the human microRNA-regulated protein-protein interaction (PPI) network by utilizing the Human Protein Reference Database (HPRD) and the miRNA target prediction program TargetScan \[[@B10]\]. They found that an individual miRNA often targets the hub gene of the PPI network, although they did not attempt to characterize relevant pathways, diseases, and pathological events regulated by miRNA target genes.

At present, the question remains to be fully elucidated whether a set of miRNA target genes regulated by an individual miRNA in the whole human microRNAome generally constitute the biological network of functionally-associated molecules or simply reflect a random set of functionally-independent genes. To address this question, we attempted to characterize molecular networks of target genes of all human miRNAs by using KeyMolnet, a bioinformatics tool for analyzing molecular interactions on the comprehensive knowledgebase.

Materials and methods
=====================

MicroRNA Target Prediction
--------------------------

The complete list of 1,223 human miRNAs was downloaded from miRBase Release 16 <http://www.mirbase.org>. We searched the target genes of individual miRNA on the Diana-microT 3.0 target prediction program (diana.cslab.ece.ntua.gr/microT), which was selected because of the highest ratio of correctly predicted targets over other prediction tools \[[@B11]\]. Diana-microT 3.0 calculates the miRNA-targeted gene (miTG) score that reflects the weighted sum of the scores of all conserved and non-conserved miRNA recognition elements (MRE) on the 3\'UTR of the target mRNA. The miTG score correlates well with fold changes in suppression of protein expression \[[@B11]\]. To optimize the parameter of miRNA-target interaction, we considered the target genes with a cutoff of the miTG score equal to or larger than 20 as the highly reliable targets, because we found that the targets with the miTG score \< 20 exhibited the significantly lower precision score, an indicator of correctness in predicted interactions \[[@B11]\], compared with those having the score ≧ 20 (p = 2.78E-08 by Mann-Whitney\'s U-test).

Molecular Network Analysis
--------------------------

Ensembl Gene IDs of target genes retrieved by Diana-microT 3.0 were converted into the corresponding Entrez Gene IDs by using the DAVID Bioinformatics Resources 6.7 program <http://david.abcc.ncifcrf.gov>\[[@B12]\], where non-annotated IDs were deleted. Then, Entrez Gene IDs of miRNA target genes were uploaded onto KeyMolnet.

KeyMolnet is a tool for analyzing molecular interactions on the literature-based knowledgebase that contains the contents on 123,000 molecular relationships among human genes and proteins, small molecules, diseases, pathways and drugs, established by the Institute of Medicinal Molecular Design (IMMD) (Tokyo, Japan) \[[@B13]-[@B15]\]. The core contents are collected from selected review articles and textbooks with the highest reliability, regularly updated and carefully curated by a team of expert biologists. KeyMolnet contains a panel of human canonical networks constructed by core contents in the KeyMolnet library. They represent the gold standard of the networks, composed of 430 pathways, 885 diseases, and 208 pathological events. Detailed information on all the contents is available from IMMD <http://www.immd.co.jp/en/keymolnet/index.html> upon request.

We utilized the neighboring network-search algorithm that selects the set of miRNA target genes as starting points to generate the network around starting points within one path, composed of all kinds of molecular interactions, including direct activation/inactivation, transcriptional activation/repression, and the complex formation. By uploading the list of Entrez Gene IDs onto KeyMolnet, it automatically provides corresponding molecules and a minimum set of intervening molecules as a node on networks. The generated network was compared side by side with human canonical networks described above. The algorithm that counts the number of overlapping molecules and/or molecular relations between the extracted network and the canonical network identifies the canonical network showing the most statistically significant contribution to the extracted network. This algorithm is essentially based on that of the GO::TermFinder \[[@B16]\]. The significance in the similarity between the extracted network and the canonical network is scored following the formula, where O = the number of overlapping molecules and molecular relations for the pathway or overlapping molecules alone for the disease and the pathological event between the extracted network and the canonical network, V = the number of molecules and/or molecular relations located in the extracted network, C = the number of molecules and/or molecular relations located in the canonical network, T = the number of total molecules and/or molecular relations of KeyMolnet, currently composed of approximately 15,700 molecules and 123,000 molecular relations, and the × = the sigma variable that defines coincidence.

Results
=======

Molecular Network of MicroRNA Target Genes
------------------------------------------

Among 1,223 human miRNAs examined, Diana-microT 3.0 predicted the targets from 532 miRNAs (43.5%). Among the 532 miRNAs, 273 miRNAs contained a set of highly reliable targets showing the miTG score ≧ 20. Among 273 miRNAs having reliable targets, KeyMolnet successfully extracted molecular networks from 232 miRNAs. They are comprised of 19% of total human miRNAs (microRNAome). Then, the generated network was compared side by side with human canonical networks of the KeyMolnet library, composed of 430 pathways, 885 diseases, and 208 pathological events. We found that not all 232 miRNAs contained entire categories of canonical networks because several miRNAs comprised relatively small numbers of targets. See Additional file [1](#S1){ref-type="supplementary-material"} for all the information on 232 miRNAs and their target networks. When top three pathways, diseases, and pathological events were individually totalized, the most relevant pathway is \'transcriptional regulation by RB/E2F\' (n = 39; 6.8% of total), followed by \'TGF-beta family signaling pathway\' (n = 32; 5.6%) and \'transcriptional regulation by POU domain factor\' (n = 24; 4.2%), the most relevant disease is \'adult T cell lymphoma/leukemia\' (n = 68; 12.1%), followed by \'chronic myelogenous leukemia\' (n = 65; 11.5%) and \'hepatocellular carcinoma\' (n = 51; 9.1%), and the most relevant pathological event is \'cancer\' (n = 97; 24.7%), followed by \'adipogenesis\' (n = 46; 11.7%) and \'metastasis\' (n = 36; 9.2%) (Figure [1](#F1){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"}).

![**The pathways, diseases, and pathological events relevant to 232 miRNA target networks**. Among 1,223 human miRNAs examined, Diana-microT 3.0 identified the set of reliable targets from 273 miRNAs. Among them, KeyMolnet extracted molecular networks from 232 miRNAs. The generated network was compared side by side with human canonical networks of the KeyMolnet library, composed of 430 pathways, 885 diseases, and 208 pathological events to identify the canonical network showing the most statistically significant contribution to the extracted network (see Table S1 for all the information). After top three pathways, diseases, and pathological events were individually totalized, the cumulated numbers of top 10 of **(a)**pathway, **(b)**disease, and **(c)**pathological event categories are expressed as a bar graph.](1756-0381-4-17-1){#F1}

Next, we identified the large-scale miRNA target networks by uploading targets greater than 100 per individual miRNA onto KeyMolnet (Table [1](#T1){ref-type="table"}). Fifty-two miRNAs that construct such a large-scale miRNA target network include let-7, miR-9, 17, 19, 20, 26, 27, 29, 30, 32, 92, 93, 96, 98, 101, 106b, 124, 137, 147, 153, 218, 372, 429, 495, 506, 519, 520, 603, and their closely-related family members. The targets of these miRNAs established highly complex molecular networks, in which the pathways of \'transcriptional regulation by RB/E2F\', \'transcriptional regulation by Ets-domain family\', and \'transcriptional regulation by p53\', the diseases of \'chronic myelogenous leukemia\' and \'viral myocarditis\', and the pathological event of \'cancer\' were notably accumulated (Table [1](#T1){ref-type="table"}). Importantly, distinct members belonging to the same miRNA family, for example, five miR-30 family members ranging from miR-30a to miR-30e constructed a virtually identical molecular network (Table [1](#T1){ref-type="table"}).

###### 

The large-scale human microRNA target networks

  MicroRNA          Number of Targets   Molecules in KeyMolnet Networks   Top Pathway                                       Score   p-Value     Top Disease                      Score   p-Value    Top Pathological Event              Score   p-Value
  ----------------- ------------------- --------------------------------- ------------------------------------------------- ------- ----------- -------------------------------- ------- ---------- ----------------------------------- ------- ----------
  hsa-let-7a        244                 1022                              Transcriptional regulation by p53                 593     2.69E-179   Viral myocarditis                113     1.21E-34   Cancer                              206     1.31E-62
                                                                                                                                                                                                                                                
  hsa-let-7b        242                 1016                              Transcriptional regulation by p53                 594     1.83E-179   Viral myocarditis                113     9.32E-35   Cancer                              206     7.66E-63
                                                                                                                                                                                                                                                
  hsa-let-7c        243                 1020                              Transcriptional regulation by p53                 593     2.49E-179   Viral myocarditis                113     1.11E-34   Cancer                              206     1.10E-62
                                                                                                                                                                                                                                                
  hsa-let-7d        145                 885                               Transcriptional regulation by RB/E2F              836     2.18E-252   Chronic myelogenous leukemia     72      1.95E-22   Cancer                              130     9.68E-40
                                                                                                                                                                                                                                                
  hsa-let-7e        236                 1111                              Transcriptional regulation by p53                 575     8.90E-174   Viral myocarditis                116     1.20E-35   Cancer                              175     1.86E-53
                                                                                                                                                                                                                                                
  hsa-let-7f        244                 1022                              Transcriptional regulation by p53                 593     2.69E-179   Viral myocarditis                113     1.21E-34   Cancer                              206     1.31E-62
                                                                                                                                                                                                                                                
  hsa-let-7g        245                 1022                              Transcriptional regulation by p53                 593     2.69E-179   Viral myocarditis                113     1.21E-34   Cancer                              206     1.31E-62
                                                                                                                                                                                                                                                
  hsa-let-7i        245                 1022                              Transcriptional regulation by p53                 593     2.69E-179   Viral myocarditis                113     1.21E-34   Cancer                              206     1.31E-62
                                                                                                                                                                                                                                                
  hsa-miR-9         352                 1115                              Transcriptional regulation by PPARa               340     5.28E-103   Hepatocellular carcinoma         72      1.69E-22   Cancer                              171     3.50E-52
                                                                                                                                                                                                                                                
  hsa-miR-17        195                 961                               Transcriptional regulation by RB/E2F              971     3.27E-293   Chronic myelogenous leukemia     92      2.83E-28   Cancer                              181     3.58E-55
                                                                                                                                                                                                                                                
  hsa-miR-19a       226                 1094                              Transcriptional regulation by RB/E2F              760     2.10E-229   Chronic myelogenous leukemia     113     1.26E-34   Cancer                              253     7.04E-77
                                                                                                                                                                                                                                                
  hsa-miR-19b       225                 1094                              Transcriptional regulation by RB/E2F              760     2.10E-229   Chronic myelogenous leukemia     113     1.26E-34   Cancer                              253     7.04E-77
                                                                                                                                                                                                                                                
  hsa-miR-20a       165                 1038                              Transcriptional regulation by RB/E2F              856     1.64E-258   Chronic myelogenous leukemia     87      6.09E-27   Cancer                              85      3.33E-26
                                                                                                                                                                                                                                                
  hsa-miR-20b       198                 981                               Transcriptional regulation by RB/E2F              962     2.35E-290   Chronic myelogenous leukemia     98      3.39E-30   Cancer                              183     6.98E-56
                                                                                                                                                                                                                                                
  hsa-miR-26a       148                 672                               Transcriptional regulation by RB/E2F              919     1.76E-277   Chronic myelogenous leukemia     107     6.15E-33   Cancer                              181     3.20E-55
                                                                                                                                                                                                                                                
  hsa-miR-26b       148                 672                               Transcriptional regulation by RB/E2F              919     1.76E-277   Chronic myelogenous leukemia     107     6.15E-33   Cancer                              181     3.20E-55
                                                                                                                                                                                                                                                
  hsa-miR-27a       229                 1192                              Transcriptional regulation by CREB                1022    2.23E-308   Chronic myelogenous leukemia     95      1.96E-29   Cancer                              194     3.05E-59
                                                                                                                                                                                                                                                
  hsa-miR-27b       261                 1337                              Transcriptional regulation by CREB                1022    2.23E-308   Chronic myelogenous leukemia     94      4.51E-29   Cancer                              211     4.11E-64
                                                                                                                                                                                                                                                
  hsa-miR-29a       119                 543                               Transcriptional regulation by Ets-domain family   430     4.36E-130   Glioma                           85      3.46E-26   Cancer                              139     1.41E-42
                                                                                                                                                                                                                                                
  hsa-miR-29b       118                 578                               Transcriptional regulation by Ets-domain family   422     1.15E-127   Glioma                           82      1.55E-25   Cancer                              146     1.44E-44
                                                                                                                                                                                                                                                
  hsa-miR-29c       118                 543                               Transcriptional regulation by Ets-domain family   430     4.36E-130   Glioma                           85      3.46E-26   Cancer                              139     1.41E-42
                                                                                                                                                                                                                                                
  hsa-miR-30a       455                 1494                              Transcriptional regulation by RB/E2F              777     9.43E-235   Chronic myelogenous leukemia     86      1.11E-26   Cancer                              195     2.39E-59
                                                                                                                                                                                                                                                
  hsa-miR-30b       455                 1480                              Transcriptional regulation by RB/E2F              781     1.08E-235   Chronic myelogenous leukemia     87      7.01E-27   Cancer                              188     1.92E-57
                                                                                                                                                                                                                                                
  hsa-miR-30c       454                 1495                              Transcriptional regulation by RB/E2F              778     6.13E-235   Chronic myelogenous leukemia     86      1.15E-26   Cancer                              191     3.63E-58
                                                                                                                                                                                                                                                
  hsa-miR-30d       452                 1491                              Transcriptional regulation by RB/E2F              778     7.28E-235   Chronic myelogenous leukemia     86      1.01E-26   Cancer                              195     1.96E-59
                                                                                                                                                                                                                                                
  hsa-miR-30e       455                 1481                              Transcriptional regulation by RB/E2F              780     1.29E-235   Chronic myelogenous leukemia     87      7.25E-27   Cancer                              188     2.05E-57
                                                                                                                                                                                                                                                
  hsa-miR-32        261                 905                               Transcriptional regulation by RB/E2F              842     2.74E-254   Gastric cancer                   80      8.85E-25   Cancer                              157     4.19E-48
                                                                                                                                                                                                                                                
  hsa-miR-92a       219                 642                               Transcriptional regulation by MEF2                335     1.51E-101   Viral myocarditis                59      1.62E-18   Epithelial-mesenchymal transition   83      7.76E-26
                                                                                                                                                                                                                                                
  hsa-miR-92b       258                 701                               Transcriptional regulation by MEF2                328     1.59E-99    Viral myocarditis                60      1.23E-18   Cancer                              94      3.97E-29
                                                                                                                                                                                                                                                
  hsa-miR-93        195                 958                               Transcriptional regulation by RB/E2F              972     2.37E-293   Chronic myelogenous leukemia     92      2.47E-28   Cancer                              181     2.77E-55
                                                                                                                                                                                                                                                
  hsa-miR-96        142                 688                               Transcriptional regulation by Ets-domain family   407     3.42E-123   Viral myocarditis                36      1.06E-11   Cancer                              106     1.37E-32
                                                                                                                                                                                                                                                
  hsa-miR-98        162                 671                               Transcriptional regulation by Myb                 549     4.73E-166   Viral myocarditis                85      2.66E-26   Cancer                              126     1.42E-38
                                                                                                                                                                                                                                                
  hsa-miR-101       188                 806                               Transcriptional regulation by AP-1                492     1.10E-148   Hepatocellular carcinoma         70      6.40E-22   Cancer                              127     4.26E-39
                                                                                                                                                                                                                                                
  hsa-miR-106b      164                 1028                              Transcriptional regulation by RB/E2F              854     7.21E-258   Chronic myelogenous leukemia     87      5.48E-27   Cancer                              85      2.93E-26
                                                                                                                                                                                                                                                
  hsa-miR-124       285                 1346                              Transcriptional regulation by RB/E2F              756     3.57E-228   Chronic myelogenous leukemia     83      9.34E-26   Cancer                              185     1.90E-56
                                                                                                                                                                                                                                                
  hsa-miR-137       288                 941                               Transcriptional regulation by MITF family         339     1.19E-102   Adult T cell lymphoma/leukemia   66      1.30E-20   Cancer                              179     1.00E-54
                                                                                                                                                                                                                                                
  hsa-miR-147       199                 867                               Transcriptional regulation by RB/E2F              805     4.06E-243   Chronic myelogenous leukemia     113     6.60E-35   Cancer                              132     2.57E-40
                                                                                                                                                                                                                                                
  hsa-miR-153       154                 1019                              Transcriptional regulation by Myb                 507     2.35E-153   Multiple myeloma                 60      6.44E-19   Cancer                              174     4.31E-53
                                                                                                                                                                                                                                                
  hsa-miR-218       155                 830                               Transcriptional regulation by AP-1                344     2.28E-104   Hepatocellular carcinoma         69      1.63E-21   Cancer                              136     1.52E-41
                                                                                                                                                                                                                                                
  hsa-miR-372       101                 562                               Transcriptional regulation by RB/E2F              1022    2.23E-308   Chronic myelogenous leukemia     85      1.90E-26   Cancer                              144     2.75E-44
                                                                                                                                                                                                                                                
  hsa-miR-429       123                 634                               Transcriptional regulation by RB/E2F              918     2.45E-277   Chronic myelogenous leukemia     76      1.71E-23   Cancer                              130     5.28E-40
                                                                                                                                                                                                                                                
  hsa-miR-495       156                 601                               Transcriptional regulation by Ets-domain family   431     2.14E-130   Rheumatoid arthritis             77      5.90E-24   Adipogenesis                        79      1.32E-24
                                                                                                                                                                                                                                                
  hsa-miR-506       394                 1536                              Transcriptional regulation by Ets-domain family   317     4.69E-96    Viral myocarditis                99      1.73E-30   Cancer                              172     1.43E-52
                                                                                                                                                                                                                                                
  hsa-miR-519a      281                 1256                              Transcriptional regulation by RB/E2F              811     5.32E-245   Chronic myelogenous leukemia     106     1.34E-32   Cancer                              220     8.03E-67
                                                                                                                                                                                                                                                
  hsa-miR-519b-3p   281                 1256                              Transcriptional regulation by RB/E2F              811     5.32E-245   Chronic myelogenous leukemia     106     1.34E-32   Cancer                              220     8.03E-67
                                                                                                                                                                                                                                                
  hsa-miR-519c-3p   281                 1256                              Transcriptional regulation by RB/E2F              811     5.32E-245   Chronic myelogenous leukemia     106     1.34E-32   Cancer                              220     8.03E-67
                                                                                                                                                                                                                                                
  hsa-miR-520a-3p   184                 690                               Transcriptional regulation by RB/E2F              1022    2.23E-308   Chronic myelogenous leukemia     94      6.95E-29   Cancer                              146     1.12E-44
                                                                                                                                                                                                                                                
  hsa-miR-520b      182                 690                               Transcriptional regulation by RB/E2F              1022    2.23E-308   Chronic myelogenous leukemia     94      6.95E-29   Cancer                              146     1.12E-44
                                                                                                                                                                                                                                                
  hsa-miR-520c-3p   182                 690                               Transcriptional regulation by RB/E2F              1022    2.23E-308   Chronic myelogenous leukemia     93      9.28E-29   Cancer                              145     1.77E-44
                                                                                                                                                                                                                                                
  hsa-miR-520d-3p   183                 690                               Transcriptional regulation by RB/E2F              1022    2.23E-308   Chronic myelogenous leukemia     94      6.95E-29   Cancer                              146     1.12E-44
                                                                                                                                                                                                                                                
  hsa-miR-520e      184                 690                               Transcriptional regulation by RB/E2F              1022    2.23E-308   Chronic myelogenous leukemia     94      6.95E-29   Cancer                              146     1.12E-44
                                                                                                                                                                                                                                                
  hsa-miR-603       252                 1150                              Transcriptional regulation by Ets-domain family   344     3.26E-104   Multiple myeloma                 84      4.36E-26   Cancer                              161     4.24E-49

Among 1,223 human miRNAs examined, Diana-microT 3.0 predicted reliable targets from 273 miRNAs. Among them, KeyMolnet extracted molecular networks from 232 miRNAs. The generated network was compared side by side with human canonical networks of the KeyMolnet library, composed of 430 pathways, 885 diseases, and 208 pathological events. The canonical pathways, diseases, and pathological events with the most statistically significant contribution to the extracted network are shown. The table contains only the large-scale miRNA target networks generated by importing targets greater than 100 per individual miRNA into KeyMolnet. See Additional file [1](#S1){ref-type="supplementary-material"} for all the information on 232 miRNAs and their target networks.

Biological Implications of MicroRNA Target Networks
---------------------------------------------------

As described above, the present observations indicated that a set of miRNA target genes regulated by an individual miRNA generally constitute the biological network of functionally-associated molecules in human cells. Therefore, it is highly important to obtain deeper insights into biological implications of miRNA target networks.

The protooncogene c-myb is a key transcription factor for normal development of hematopoietic cells. A recent study showed that miR-15a targets c-myb, while c-myb binds to the promoter of miR-15a, providing an autoregulatory feedback loop in human hematopoietic cells \[[@B17]\]. Consistent with this study, we found \'transcriptional regulation by myb\' as the most relevant pathway to the miR-15a target network (the score = 602; the score p-value = 7.39E-182) (Figure [2](#F2){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"}). These observations propose a scenario that miR-15a synchronously downregulates both c-myb itself and downstream genes transcriptionally regulated by c-myb, resulting in efficient inactivation of the whole molecular network governed by the hub gene c-myb. These results suggest a collaborative regulation of gene expression at both transcriptional and posttranscriptional levels that involve coordinated regulation by miRNAs and transcription factors.

![**Molecular network of miR-15a targets**. By the \"neighboring\" network-search algorithm, KeyMolnet illustrated a highly complex network of miR-15a targets that has the most statistically significant relationship with the pathway of \'transcriptional regulation by myb\'. Red nodes represent miR-15a direct target molecules predicted by Diana-microT 3.0, whereas white nodes exhibit additional nodes extracted automatically from the core contents of KeyMolnet to establish molecular connections. The molecular relation is indicated by solid line with arrow (direct binding or activation), solid line with arrow and stop (direct inactivation), solid line without arrow (complex formation), dash line with arrow (transcriptional activation), and dash line with arrow and stop (transcriptional repression). The transcription factor myb is highlighted by a blue circle.](1756-0381-4-17-2){#F2}

The retinoblastoma protein Rb/E2F pathway acts as a gatekeeper for G1/S transition in the cell cycle. The Rb/E2F-regulated G1 checkpoint control is often disrupted in cancer cells. A recent study showed that miR-106b is directly involved in posttranscriptional regulation of E2F1 \[[@B18]\]. E2F1 activates transcription of miR-106b, while miR-106b targets E2F1, serving as a miRNA-directed negative feedback loop in gastric cancer cells \[[@B18]\]. Supporting these findings, we identified \'transcriptional regulation by Rb/E2F\' as the most relevant pathway to the miR-106b target network (the score = 854; the score p-value = 7.21E-258) (Figure [3,](#F3){ref-type="fig"} Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}). The relationship between miR-106b and Rb/E2F would provide another example of coordinated regulation of gene expression by miRNAs and transcription factors.

![**Molecular network of miR-106b targets**. By the \"neighboring\" network-search algorithm, KeyMolnet illustrated a highly complex network of miR-106b targets that has the most statistically significant relationship with the pathway of \'transcriptional regulation by Rb/E2F\'. Red nodes represent miR-106b direct target molecules predicted by Diana-microT 3.0, whereas white nodes exhibit additional nodes extracted automatically from the core contents of KeyMolnet to establish molecular connections. The molecular relation is indicated by solid line with arrow (direct binding or activation), solid line with arrow and stop (direct inactivation), solid line without arrow (complex formation), dash line with arrow (transcriptional activation), and dash line with arrow and stop (transcriptional repression). The transcription factor E2F is highlighted by a blue circle.](1756-0381-4-17-3){#F3}

We found \'transcriptional regulation by p53\' as the most relevant pathway to the target network of all let-7 family members except for let-7d (Table [1](#T1){ref-type="table"}). It is worthy to note that the tumor suppressor p53 regulates the expression of components of the miRNA-processing machinery, such as Drosha, DGCR8, Dicer, and TARBP2, all of which have p53-reponsive elements in their promoters \[[@B19]\]. Furthermore, Dicer and TARBP2, along with p53, serve as a target of the let-7 family miRNAs, suggesting a close link between p53 and let-7 in miRNA biogenesis \[[@B19]\]. The expression of let-7 family members was greatly reduced in certain cancer cells \[[@B20]\].

The micropthalmia associated transcription factor (MITF), a basic helix-loop-helix zipper (bHLH-Zip) transcription factor, acts as not only a master regulator of melanocyte differentiation but also an oncogene promoting survival of melanoma. Recent studies indicate that MITF is a direct target of both miR-137 and miR-148b \[[@B21],[@B22]\]. Again, we identified \'transcriptional regulation by MITF family\' as the most relevant pathway to both miR-137 (the score = 339; the score p-value = 1.19E-102) and miR-148b (the score = 40; the score p-value = 3.91E-142) target networks (Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}).

Cellular responsiveness to glucocorticoids (GCs) is regulated by the delicate balance of the glucocorticoid receptor (GR) protein, GR coactivators and corepressors, GR splice variants and isoforms, and regulators of GR retrograde transport to the nucleus. A recent study showed that miR-18a targets the GR protein, and thereby inhibits GR-mediated biological events in neuronal cells \[[@B23]\]. Consistent with this, we found \'transcriptional regulation by GR\' as the most relevant pathway to the miR-18a target network (the score = 1022; the score p-value = 2.23E-308) (Additional file [1](#S1){ref-type="supplementary-material"}).

Zinc finger transcription factors ZEB1 and ZEB2 act as a transcriptional repressor of E-cadherin. A recent study showed that the expression of miR-200b, which targets both ZEB1 and ZEB2, was downregulated in the cells that undergo TGF-beta-induced epithelial to mesenchymal transition (EMT), and was lost in invasive breast cancer cells \[[@B24]\]. We identified \'transcriptional regulation by ZEB\' as the third-rank significant pathway (the score = 155; the score p-value = 1.88E-47) and \'EMT\' as the third-rank significant pathological event relevant to the miR-200b target network (the score = 61; the score p-value = 4.15E-19) (Additional file [1](#S1){ref-type="supplementary-material"}).

Discussion
==========

In general, a single miRNA concurrently downregulates hundreds of target mRNAs by binding to the corresponding 3\'UTR of mRNA via either perfect or imperfect sequence complementarity \[[@B3]\]. Such fuzzy mRNA-miRNA interactions result in the redundancy of miRNA-recognized targets. By targeting multiple transcripts and affecting expression of numerous proteins at one time, miRNAs regulate a wide range of cellular functions, such as development, differentiation, proliferation, apoptosis and metabolism. Therefore, we have the question whether a set of miRNA target genes regulated by an individual miRNA generally constitute the biological network of functionally-associated molecules or simply reflect a random set of functionally-independent genes. If the former is the case, what kind of biological networks does the human microRNAome most actively regulates?

To address these questions, first we identified the set of credible target genes for all individual human miRNAs by using the Diana-microT 3.0 program. Then, we investigated miRNA target networks by applying them to KeyMolnet, a bioinformatics tool for analyzing molecular interactions on the comprehensive knowledgebase. Diana-microT 3.0 identified highly reliable targets from 273 miRNAs out of 1,223 all human miRNAs. Previous studies showed that the list of predicted targets for each miRNA varies among different miRNA target prediction programs armed with distinct algorithms, such as TargetScan 5.1 <http://www.targetscan.org>, PicTar (pictar.mdc-berlin.de), miRanda <http://www.microrna.org> and Diana-microT 3.0 \[[@B25]\]. Therefore, miRNA target networks are to some extent flexible, depending on the target prediction program employed. Among the programs described above, we have chosen Diana-microT 3.0 because of the highest ratio of correctly predicted targets over other prediction tools and the simplicity of setting a cut-off point for detection of reliable miRNA-target interactions based on the miTG score \[[@B11]\].

Here we found that highly reliable targets of substantial numbers of human miRNAs actually constructed biologically meaningful molecular networks. These observations strongly supported the theoretical view that miRNA target genes regulated by an individual miRNA in the whole human microRNAome generally constitute the biological network of functionally-associated molecules. A recent study showed that interacting proteins in the human PPI network tend to share restricted miRNA target-site types than random pairs, being consistent with our observations \[[@B26]\].

We also found that there exists a coordinated regulation of gene expression at the transcriptional level by transcription factors and at the posttranscriptional level by miRNAs in miRNA target networks. Recently, Cui et al. investigated the relationship between miRNA and transcription factors in gene regulation \[[@B27]\]. Importantly, they found that the genes with more transcription factor-binding sites have a higher probability of being targeted by miRNAs and have more miRNA-binding sites.

A recent study by miRNA expression profiling of thousands of human tissue samples revealed that diverse miRNAs constitute a complex network composed of coordinately regulated miRNA subnetworks in both normal and cancer tissues, and they are often disorganized in solid tumors and leukemias \[[@B28]\]. During carcinogenesis, various miRNAs play a central role, acting as either oncogenes named oncomir or tumor suppressors termed anti-oncomir, by targeting key molecules involved in apoptosis, cell cycle, cell adhesion and migration, chromosome stability, and DNA repair \[[@B5]\]. Many miRNA gene loci are clustered in cancer-associated genomic regions \[[@B29]\]. Furthermore, miRNA expression signatures well discriminate different types of cancers with distinct clinical prognoses \[[@B30]\]. In the present study, KeyMolnet analysis of miRNA target networks showed that the most relevant pathological event is \'cancer\', when top three pathological events were overall cumulated. Furthermore, the highly relevant diseases include \'adult T cell lymphoma/leukemia\', \'chronic myelogenous leukemia\', and \'hepatocellular carcinoma\'. These observations suggest that the human microRNAome plays a more specialized role in regulation of oncogenesis. Therefore, the miRNA-based therapy directed to targeting multiple cancer-associated pathways simultaneously might serve as the most effective approach to suppressing the oncogenic potential of a wide range of cancers.

Conclusion
==========

The reliable targets predicted by Diana microT 3.0 derived from approximately 20% of all human miRNAs constructed biologically meaningful molecular networks by KeyMolnet. These observations support the view that miRNA target genes regulated by an individual miRNA in the whole human microRNAome generally constitute the biological network of functionally-associated molecules. In the human miRNA target networks, the most relevant pathway is transcriptional regulation by transcription factors RB/E2F, the disease is adult T cell lymphoma/leukemia, and the pathological event is cancer. In miRNA target networks, there exists a coordinated regulation of gene expression at the transcriptional level by transcription factors and at the posttranscriptional level by miRNAs.
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###### Additional file 1

**KeyMolnet identifies microRNA target networks in 232 human miRNAs**. The prediction of target genes of individual miRNA was performed by Diana-microT 3.0. Entrez Gene IDs of miRNA target genes were uploaded onto KeyMolnet. The generated network was compared side by side with human canonical networks composed of 430 pathways, 885 diseases, and 208 pathological events of the KeyMolnet library. Top-three pathways, diseases, and pathological events with the statistically significant contribution to the extracted network are shown.
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